Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Other Operating Expenses (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Other Operating Expenses for 12 consecutive years, with $12.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Operating Expenses rose 10.64% year-over-year to $12.2 million, compared with a TTM value of $49.1 million through Dec 2025, up 4.2%, and an annual FY2025 reading of $49.1 million, up 4.2% over the prior year.
  • Other Operating Expenses was $12.2 million for Q4 2025 at Heron Therapeutics, down from $12.9 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $39.1 million in Q2 2022 and bottomed at $11.0 million in Q3 2024.
  • Average Other Operating Expenses over 5 years is $20.9 million, with a median of $15.2 million recorded in 2023.
  • The sharpest move saw Other Operating Expenses soared 85.71% in 2021, then crashed 60.85% in 2023.
  • Year by year, Other Operating Expenses stood at $35.4 million in 2021, then plummeted by 49.83% to $17.8 million in 2022, then plummeted by 30.64% to $12.3 million in 2023, then fell by 10.31% to $11.1 million in 2024, then rose by 10.64% to $12.2 million in 2025.
  • Business Quant data shows Other Operating Expenses for HRTX at $12.2 million in Q4 2025, $12.9 million in Q3 2025, and $11.6 million in Q2 2025.